Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities... Show more
CME Group operates the world's leading derivatives marketplace, spanning interest rates, equities, energy, agriculture, metals, and foreign exchange. Its core strength is a flywheel of deep liquidity, benchmark pricing, and central clearing that makes it the default venue for institutional risk management. Wells Fargo, which initiated coverage with an Overweight rating and a $301 price target in October 2026, framed CME Group as "the benchmark derivatives franchise," arguing that limited traction from would-be challengers reinforces its moat.
Medium-term positioning centers on extending that moat into new asset classes. The company is using its regulated, 24/7 infrastructure to capture demand in digital assets, critical minerals, and artificial-intelligence infrastructure. Morgan Stanley has highlighted single-stock futures and "compute futures" — contracts referencing Nvidia H100 and B200 chip rental costs — as secular growth vectors not yet fully reflected in the share price. These initiatives position CME Group at the intersection of financialization trends in technology and commodities, though their commercial scale remains to be proven.
Several forward-looking developments could shape investor sentiment in the coming quarters. The October 2026 launch of Bitcoin Cash (BCH) and Uniswap (UNI) futures, offered in both standard and Micro contract sizes, extends a crypto suite that averaged 195.8K contracts of daily volume in the third quarter of 2026. Separately, a planned tungsten futures contract marks the exchange's first entry into critical minerals, linking it to energy-transition supply chains.
AI compute futures represent a distinctive catalyst: by treating GPU (graphics processing unit) rental costs as a tradeable benchmark, CME Group aims to create a hedging tool for AI infrastructure — a nascent but potentially large addressable market. Cloud migration of the CME Globex platform, in partnership with Google Cloud, is another strategic inflection point that could reduce long-term cost structure and speed product development.
Analyst ratings have become more active and divergent. J.P. Morgan upgraded CME Group to Buy with a $367 price target in October 2026, while Piper Sandler and Morgan Stanley reiterated Buy ratings at $330 and $359, respectively. In contrast, Goldman Sachs maintained a Sell rating, and Deutsche Bank downgraded the stock to Hold citing valuation. Consensus data from S&P Global points to an average price target of roughly $317 with a "Buy" consensus, though the wide spread — from a low near $218 to a high near $367 — signals genuine disagreement about how much of the growth pipeline is already priced in.
CME Group's earnings are fundamentally levered to volatility and hedging demand rather than to directional market moves. Interest-rate derivatives, its largest revenue contributor, benefit when central-bank policy is uncertain, inflation is uneven, and fixed-income markets are volatile. A higher-for-longer rate environment or abrupt shifts in Federal Reserve guidance could therefore sustain elevated trading activity, while a calm, predictable rate path could dampen it.
Inflation and commodity prices also matter directly: agricultural and energy contracts respond to supply shocks and weather events, as evidenced by a record 1.2 million daily Corn futures contracts in October 2026 following a U.S. Department of Agriculture outlook update. Meanwhile, the regulatory climate for digital assets and perpetual futures remains a key swing factor. Clarity or further constraint from U.S. regulators could either unlock institutional crypto volumes or cap the growth of newer product lines, making policy a central variable in the stock's future outlook.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. The platform is designed to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors monitoring how catalysts and macro forces may translate into near-term price behavior, exploring the Trend Prediction Engine can add a data-driven layer to the research process.
Looking toward 2026 and beyond, CME Group's trajectory hinges on converting a broad pipeline of new products into durable, high-margin volume. Consensus estimates point to continued revenue and earnings-per-share (EPS) growth, with projected revenue near $7.1 billion for 2026 and roughly $7.5 billion in 2027, alongside EPS estimates rising from about $12.40 to $13.23. The exchange's high-margin, subscription-like data and clearing businesses provide a stable base, while product innovation offers optionality.
Longer term, several themes warrant attention. The tokenization of assets and 24/7 trading could widen participation across retail and institutional clients. Cloud migration and collateral-efficiency tools may support margin sustainability and cost discipline. Conversely, competition in rates and energy, the uncertain trajectory of perpetual-futures regulation, and a premium valuation relative to historical norms are the principal structural risks. As consensus expectations remain divided between bullish growth narratives and cautious valuation calls, the balance between proven cash flows and unproven new frontiers will likely define how the market prices the stock through the next cycle.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CME has been loosely correlated with ICE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CME jumps, then ICE could also see price increases.
| Ticker / NAME | Correlation To CME | 1D Price Change % | ||
|---|---|---|---|---|
| CME | 100% | +1.02% | ||
| ICE - CME | 51% Loosely correlated | +2.03% | ||
| TW - CME | 45% Loosely correlated | +1.21% | ||
| NDAQ - CME | 36% Loosely correlated | +2.25% | ||
| MKTX - CME | 35% Loosely correlated | +0.11% | ||
| MORN - CME | 26% Poorly correlated | +5.54% | ||
More | ||||
| Ticker / NAME | Correlation To CME | 1D Price Change % |
|---|---|---|
| CME | 100% | +1.02% |
| Financial Publishing/Services industry (14 stocks) | 16% Poorly correlated | -0.23% |
| Commercial Services industry (90 stocks) | 2% Poorly correlated | -0.05% |
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 54 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 26 of 47 cases over the following month. The odds of a continued upward trend are 55%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for CME moved above the 200-day moving average on October 26, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 169 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 137 of 261 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
The 10-day RSI Indicator for CME moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 17 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 69 cases where CME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 43%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.152) is normal, around the industry mean (4.113). P/E Ratio (25.843) is within average values for comparable stocks, (19.316). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.017) settles around the average of (0.017) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).